Categories: DiagnosticsNews

Relu Secures FDA 510(k) and CE Marking for Revolutionary Dental Software Relu® Creator

LEUVEN, Belgium, Oct. 1, 2024 /PRNewswire/ — Relu, a pioneer in artificial intelligence (AI) assisted segmentation for dental labs and software companies, proudly announces the dual achievement of 510(k) clearance by the U.S. Food and Drug Administration (FDA) and CE Mark approval by an EU Notified Body. These regulatory milestones authorize the commercial distribution of the Relu® Creator, the cutting-edge dental tool that enables users to create 3D anatomical models from patients in just minutes.

 

 

FDA clearance signifies compliance with U.S. medical device standards, while the CE Mark confirms adherence to EU regulations for product safety and consumer protection. This dual recognition underscores Relu’s commitment to excellence in the oral health sector.

“We are thrilled to have attained both FDA and CE approval for the Relu® Creator,” stated Adriaan Van Gerven, CTO and Co-founder, of Relu. “These significant achievements are a testament to Relu’s dedication to creating superior technology that meets the highest international safety and quality standards. We’re poised to revolutionize patient and dentist experiences across both continents.”

“This approval paves the way for our advanced technology to enter US and EU dental markets with the highest potential for growth. Having led strategy in Dental, AI and Orthodontic sectors, I consider this achievement a key differentiator that sets Relu® Creator apart. This is a major step forward in Relu’s mission to modernize dental care,” said Bindu Saran, former Global Head of Orthodontic Technology at Straumann, former Sr. Manager of R&D at Ormco, and Board Member at Relu.

The Relu® Creator integrates cutting-edge AI to deliver features such as automated anatomical identification, and enhanced 3D imaging for dental diagnostics and treatment planning. By improving precision and increasing overall efficiency in dental procedures, Relu® Creator is set to be an essential tool for modern dental clinics.

About Relu

Relu is founded in 2019 with the dream of making dental treatments safer and faster. They plug in advanced computer vision and artificial intelligence to automate manual workflows. Their Relu® Engine and Relu® Creator are used by dental lab and software partners for more than thousands of orthodontic and implant treatments every day. Relu is headquartered in Leuven, BE with an office in Boston, MA, USA. Learn more at relu.eu.

© 2024 Relu

Photo: https://healthtechnologynet.com/wp-content/uploads/2024/10/Relu.jpg
Logo: https://mma.prnewswire.com/media/2038266/Relu_Logo.jpg

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/relu-secures-fda-510k-and-ce-marking-for-revolutionary-dental-software-relu-creator-302246361.html

SOURCE Relu

Staff

Recent Posts

Attune to Support Poppy Health’s $39M ARPA-H BREATHE Project in the U.S. Schools

VIENNA, Va., Dec. 19, 2025 /PRNewswire/ -- Attune announced today that the company will play…

2 hours ago

Feel30 Launches Austin-Based Telehealth Platform for Evidence-Proven TRT & Integrated At-Home Phlebotomy Services

AUSTIN, Texas, Dec. 19, 2025 /PRNewswire/ -- Feel30 , a telehealth platform specializing in testosterone…

2 hours ago

LISA LING JOINS TENDERCARE AS CHIEF CAREGIVER ADVOCATE & ADVISOR

– Will help address the difficult realities sandwich generation caregivers face with family caregiving –NEW…

2 hours ago

TENDERCARE LAUNCHING NATIONAL FAMILY CAREGIVING INFRASTRUCTURE, PARTNERING WITH THE AGING LIFE CARE ASSOCIATION® AND SUPPORTING THE CMS GUIDE MODEL PROGRAM

tendercare partnering with ALCA to raise national caregiving and eldercare industry standards;Selected as CMS GUIDE…

2 hours ago

HCAP Partners Announces Investment in Puzzle Healthcare

Investment to accelerate the growth of a post-acute care platform focused on reducing hospital readmissions…

2 hours ago

The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute

IRVING, Texas, Dec. 19, 2025 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation…

2 hours ago